VXM 01

Drug Profile

VXM 01

Alternative Names: VEGFR2 peptide vaccine - VAXIMM; VEGFR2 specific T cell vaccine; VXM-01

Latest Information Update: 30 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Pfizer; VAXIMM
  • Class Cancer vaccines; DNA vaccines; Peptide vaccines
  • Mechanism of Action Angiogenesis inhibitors; T lymphocyte stimulants; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • Phase I Colorectal cancer
  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 10 Oct 2018 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Second-line therapy or greater) in Germany (PO) (EudraCT2017-003076-31)
  • 21 Sep 2018 VAXIMM collaborates with CMS for the development and commercialisation of VAXIMM’s oral cancer immunotherapy candidates in China and other Asian countries excluding Japan
  • 01 Jul 2018 Vaximm completes a phase-I trial in Glioblastoma (Late-stage disease, Second-line therapy or greater, Recurrent) in Germany (PO) ( NCT02718443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top